FANG-2018-CAMRELIZUMAB-NPC
Regimen
- Experimental
- Camrelizumab monotherapy (escalating doses, expansion at 200 mg q2w) OR camrelizumab + gemcitabine/cisplatin (GP) combination
- Control
- none
Population
Two separate NPC cohorts: (1) 93 patients with recurrent/metastatic NPC receiving camrelizumab monotherapy across dose-escalation and expansion; (2) 23 treatment-naive patients receiving camrelizumab + GP combination
Key finding
The Fang 2018 phase 1 study provided the critical early evidence for camrelizumab's activity in NPC, generating the hypothesis for CAPTAIN-1st. The 34% ORR for monotherapy in heavily pretreated patients and near-complete 91% ORR for the treatment-naive combination cohort were landmark signals from Hengrui's domestic Chinese PD-1. Camrelizumab is the specific drug — not toripalimab or tislelizumab.
Source: PMID 30213452